U.S. FDA Mulls Joint Action With India’s DCGI For Closer Scrutiny Of Clinical Research Organizations
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After setting up a full-fledged India office, U.S. FDA is now planning to initiate its Bioresearch Monitoring Program aimed at comprehensive on-site inspections and data audits designed to monitor all aspects of U.S. FDA-regulated research